Angiotensin II 5-valine

Product Name:Angiotensin II 5-valine

Form:Acetate salt

Purity:95%

Storage:-20^oC

Cas No:58-49-1

Molar Mass:1032.2

Chemical Formula:C49H69N13O12

IUPAC Name:(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid

SMILES:CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N

InChIKey:NLPUTBDZNNXHCO-CGHBYZBKSA-N

InChI:InChI=1S/C49H69N13O12/c1-26(2)39(60-42(67)33(12-8-18-54-49(51)52)56-41(66)32(50)23-38(64)65)45(70)57-34(20-29-14-16-31(63)17-15-29)43(68)61-40(27(3)4)46(71)58-35(22-30-24-53-25-55-30)47(72)62-19-9-13-37(62)44(69)59-36(48(73)74)21-28-10-6-5-7-11-28/h5-7,10-11,14-17,24-27,32-37,39-40,63H,8-9,12-13,18-23,50H2,1-4H3,(H,53,55)(H,56,66)(H,57,70)(H,58,71)(H,59,69)(H,60,67)(H,61,68)(H,64,65)(H,73,74)(H4,51,52,54)/t32-,33-,34-,35-,36-,37-,39-,40-/m0/s1

Sequence:DRVYVHPF

Application:Angiotensin II 5-valine (Val?-Angiotensin II) is a modified peptide analog of angiotensin II, a key regulator of the renin-angiotensin system (RAS) involved in blood pressure control, fluid balance, and cardiovascular function. This variant exhibits enhanced receptor selectivity and altered vasoconstrictive properties, making it a subject of study in hypertension, heart failure, and renal disorders. It primarily acts on angiotensin II type 1 (AT1) and type 2 (AT2) receptors, influencing vascular tone and aldosterone secretion. Current research explores its therapeutic potential in cardiovascular diseases, kidney function modulation, and metabolic syndrome, positioning it as a promising candidate in precision medicine.

Reference:Khosla, M. C., Smeby, R. R., & Bumpus, F. M. (1974). Structure-activity relationship in angiotensin II analogs. In?angiotensin?(pp. 126-161). Berlin, Heidelberg: Springer Berlin Heidelberg.